Welcome to our dedicated page for Ascendis Pharma SEC filings (Ticker: ASND), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Ascendis Pharma A/S (ASND) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a foreign private issuer listed on Nasdaq. Ascendis files annual reports on Form 20-F and furnishes interim updates on Form 6-K, which include clinical, regulatory, financial, and corporate information related to its TransCon-based therapies.
In these filings, investors can review details on Ascendis’ pharmaceutical preparation manufacturing activities, including revenue from commercial products such as YORVIPATH (TransCon PTH) for adults with hypoparathyroidism and SKYTROFA (TransCon hGH) for growth hormone deficiency. Unaudited condensed consolidated interim financial statements, management’s discussion and analysis, and segment information by geography (North America, Europe, and rest of world) are typically included in quarterly 6-K submissions.
Filings also describe the status of key pipeline programs like TransCon CNP for children with achondroplasia, combination therapy with TransCon CNP and TransCon hGH in the COACH trial, and TransCon IL-2 β/γ in oncology, along with updates on regulatory reviews by the U.S. Food and Drug Administration and the European Medicines Agency. Additional 6-Ks may cover warrant grants, share capital changes, and the operation of equity compensation plans and share repurchase programs.
Stock Titan enhances these documents with AI-powered summaries that highlight the main points of lengthy 20-F and 6-K filings, helping users quickly understand revenue drivers, operating results, and key clinical or regulatory events. Real-time updates from EDGAR ensure that new Ascendis filings, including financial statements and other material disclosures, are available promptly, while structured access makes it easier to locate specific reports relevant to ASND analysis.
Ascendis Pharma A/S reported the grant of 41,220 warrants to certain employees under Appendix 1a of its Articles of Association. Each warrant entitles the holder to subscribe for one ordinary share at an exercise price of US $201.16 per share, equal to the closing price of the ADS representing the company’s ordinary shares on the grant date.
The vesting schedule provides that 25% of the warrants vest on the one-year anniversary of the grant, with the remaining 75% vesting in equal monthly installments over the subsequent 36 months, subject to continued service. Certain exit events may cause earlier vesting as provided in the Articles of Association. Following this grant, warrants to subscribe for an additional 1,753,053 shares remain available for future grant pursuant to the Articles. The Articles of Association were amended to provide for this grant and are furnished as Exhibit 1.1.
Ascendis Pharma A/S furnished unaudited Q3 2025 results via Form 6-K. Revenue rose to €213.6M (from €57.8M a year ago), driven mainly by commercial products. Q3 gross profit was €191.3M and operating profit reached €11.0M versus an operating loss last year. The quarter ended with a net loss of €61.0M and basic EPS of €(1.00).
For the nine months, revenue was €472.6M with a net loss of €194.5M and EPS of €(3.22). Product sales led results: YORVIPATH €143.1M and SKYTROFA €50.7M in Q3; North America contributed €161.1M of Q3 revenue. Cash and cash equivalents were €539.1M as of September 30, 2025. The balance sheet shows total liabilities of €1,328.8M and negative equity of €174.1M. Key financing items include convertible senior notes (€426.2M carrying amount), royalty funding liabilities (€287.8M), and derivative liabilities (€233.8M). Management states existing capital resources are expected to cover projected needs for at least twelve months from the report date.
Ascendis Pharma A/S filed a Form 6-K to provide investors with a press release reporting its financial results for the fiscal quarter ended September 30, 2025. The press release is furnished as Exhibit 99.1 and is dated November 12, 2025.
The filing indicates that Ascendis Pharma prepares its annual reports under cover of Form 20-F and uses this Form 6-K to make its quarterly financial information available to the market.
Ascendis Pharma (ASND) reported a product update via Form 6-K. The company announced commercial availability of SKYTROFA (TransCon hGH) in broader dosing ranges in the United States. The therapy is indicated for the replacement of endogenous growth hormone in adults with growth hormone deficiency.
The report is also incorporated by reference into the company’s effective Form S-8 and Form F-3 registration statements.
Ascendis Pharma (ASND) reported a new employee equity grant. On October 14, 2025, the board granted 31,710 warrants under Appendix 1a of the Articles of Association. Each warrant entitles the holder to subscribe for one ordinary share at an exercise price of $208.71 per share, set at the ADS closing price on the grant date.
The company amended its Articles of Association to provide for this grant. Vesting follows a standard schedule: 25% on the one-year anniversary, then 1/36th monthly for the next three years, subject to continued service and earlier vesting upon certain exit events. After this grant, 1,794,273 warrants remain available for future grants pursuant to the Articles of Association.
Ascendis Pharma A/S reports that it has submitted a Marketing Authorisation Application to the European Medicines Agency for TransCon CNP (navepegritide) as a treatment for children with achondroplasia. Achondroplasia is described as a rare genetic condition that causes skeletal dysplasia and can significantly affect health, physical functioning, and quality of life.
TransCon CNP is an investigational, once-weekly prodrug of C-type natriuretic peptide designed to provide continuous exposure of active CNP throughout the body, including growth plates and skeletal muscle, with the goal of continuously inhibiting the overactive FGFR3 pathway that drives achondroplasia. The filing also notes that this 6-K is incorporated by reference into Ascendis Pharma’s existing Form S-8 and Form F-3 registration statements.
Ascendis Pharma A/S reports that a warrant exercise window for its outstanding warrants closed on September 29, 2025. During this window, certain warrants were exercised for ordinary shares with a nominal value of DKK 1.
As a result, Ascendis registered aggregate share capital increases of nominal DKK 543,748 with the Danish Business Authority, bringing total share capital to nominal DKK 61,695,211 through the issuance of 543,748 ordinary shares. These shares were issued against average cash consideration of approximately USD $97.45 per share, and the company’s articles of association were amended accordingly.
Ascendis Pharma A/S furnished its Articles of Association as an exhibit to the Form 6-K and stated that those articles are to be incorporated by reference into multiple registration statements, specifically a series of S-8 filings and two Form F-3 filings listed in the report. The exhibit is signed by the company’s Executive Vice President, Chief Legal Officer to confirm the submission. This report supplies corporate governance documentation for use in the company’s existing registration statements and related prospectuses.
Form 144 filing for Ascendis Pharma A/S (ASND) shows proposed and recent officer-related sales of American Depositary Shares (ADS). The filing lists a proposed sale of 5,000 ADS through Merrill Lynch on 09/09/2025 with an aggregate market value of $1,018,503.05. The 5,000 ADS were acquired on 09/09/2025 via warrant exercise from Ascendis Pharma A/S and paid for in cash the same day. The filer also reported a sale on 08/13/2025 of 10,000 ADS for gross proceeds of $1,913,224.99. The notice includes the filer’s representation that they are not aware of undisclosed material adverse information about the issuer.
Insider notice of proposed sale under Rule 144 for Ascendis Pharma A/S (ASND). The filing shows 5,000 American Depositary Shares acquired via warrant exercise and to be sold through Merrill Lynch on NASDAQ with an aggregate market value of $965,000. The filer previously sold 9,375 ADS for $1,826,403.05 earlier in August. The filing discloses the acquisition method (warrant exercise), the broker, the number of shares outstanding (60,454,589) and that payment for the exercised ADS was in cash. The signer also represents they have no undisclosed material adverse information about the issuer.